- Home
- NRIX vs SMBK Comparison
NRIX vs SMBK Comparison
Compare NRIX & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- SMBK
- Stock Information
- Founded
- NRIX 2009
- SMBK N/A
- Country
- NRIX United States
- SMBK United States
- Employees
- NRIX N/A
- SMBK N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- SMBK Major Banks
- Sector
- NRIX Health Care
- SMBK Finance
- Exchange
- NRIX Nasdaq
- SMBK Nasdaq
- Market Cap
- NRIX 728.6M
- SMBK 602.3M
- IPO Year
- NRIX 2020
- SMBK N/A
- Fundamental
- Price
- NRIX $8.97
- SMBK $37.81
- Analyst Decision
- NRIX Strong Buy
- SMBK Buy
- Analyst Count
- NRIX 14
- SMBK 4
- Target Price
- NRIX $29.07
- SMBK $37.25
- AVG Volume (30 Days)
- NRIX 847.4K
- SMBK 40.9K
- Earning Date
- NRIX 10-10-2025
- SMBK 10-20-2025
- Dividend Yield
- NRIX N/A
- SMBK 0.85%
- EPS Growth
- NRIX N/A
- SMBK 62.51
- EPS
- NRIX N/A
- SMBK 2.47
- Revenue
- NRIX $88,381,000.00
- SMBK $178,959,000.00
- Revenue This Year
- NRIX $74.59
- SMBK $22.86
- Revenue Next Year
- NRIX N/A
- SMBK $10.59
- P/E Ratio
- NRIX N/A
- SMBK $15.22
- Revenue Growth
- NRIX 41.86
- SMBK 20.51
- 52 Week Low
- NRIX $8.18
- SMBK $26.31
- 52 Week High
- NRIX $29.56
- SMBK $37.89
- Technical
- Relative Strength Index (RSI)
- NRIX 42.73
- SMBK 62.29
- Support Level
- NRIX $8.33
- SMBK $36.17
- Resistance Level
- NRIX $10.13
- SMBK $37.57
- Average True Range (ATR)
- NRIX 0.49
- SMBK 0.77
- MACD
- NRIX -0.00
- SMBK -0.05
- Stochastic Oscillator
- NRIX 35.56
- SMBK 95.35
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.